CARLSBAD, Calif., July 2 /PRNewswire/ -- Chiltern, a leading global research organization, has appointed Dr. John Andrews to the role of Director, Regulatory Affairs, Americas. Dr. Andrews joins Chiltern with over 20 years experience in the pharmaceutical industry where he has held executive-level positions in the Pharma, Biotech, and CRO sectors.
Dr. Andrews will be based in Chiltern’s Wilmington, North Carolina office and will be responsible for assisting clients with strategic and tactical decisions for the most advantageous approach to develop drugs, bio-pharmaceuticals and devices. He will also be responsible for expanding Chiltern’s already mature and well-recognized Regulatory Affairs department into the North and South American continents.
Dr. Andrews earned his M.S. in biochemistry from Purdue University and his Ph.D. in microbiology from the University of North Carolina. He played a critical part in the development of AZT for the treatment of HIV disease and also pioneered combination therapies (the forerunner of HAART) and the use of viral load as a surrogate end-point for clinical drug development. Dr. Andrews has assisted in the launch of several small biotechnology, research and development companies as well as being the co-founder of PharmaResearch Corporation. More recently, Dr. Andrews held senior positions with XTL Biopharmaceuticals Inc and Beckloff Associates.
“I am very pleased to be joining Chiltern at such an exciting juncture for the company.” Dr. Andrews commented, “With FDA tightening its requirements for new applications and its scrutiny on clinical study safety results, it has become imperative for sponsors to devise unassailable development strategies, in partnerships with their CROs, in order to attain the best possible study outcome, within a predetermined timeframe.”
“I am delighted that Dr. Andrews has decided to join Chilterns’ successful Regulatory team.” declared Patricia Lovell-Hoare, Executive Vice President, Regulatory Affairs, “John’s comprehensive understanding of regulatory matters and the Pharma and CRO industries will certainly add value to the sound planning and successful conduct of sponsors clinical studies.”
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience of running and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1000 people with 18 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.
Chiltern: Understanding. For More Information Contact: Catherine Lemercier Richard Baptista Chiltern International, Inc. Chiltern International Ltd. 2111 Palomar Airport R 171 Bath Road Suite 200 Slough Carlsbad Berkshire CA 92011 SL1 4AA USA UNITED KINGDOM Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000 Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116 Email: Catherine.Lemercier@chiltern.com Email: Richard.Baptista@chiltern.com
Chiltern
CONTACT: Catherine Lemercier, +1-760-707-5025, fax, +1-760-707-5022,Catherine.Lemercier@chiltern.com, or Richard Baptista, +44 (0) 1753 512000, fax, +44 (0) 1753 511 116, Richard.Baptista@chiltern.com, both ofChiltern
Web site: http://www.chiltern.com/
